Quanterix Presenting at Canaccord Genuity 44th Annual Growth Conference
The presentation will be available virtually and participants can register using this link. The presentation will be available following the conference on Quanterix’s website here.
To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix’s Simoa® technology, visit: https://www.quanterix.com/simoa-technology/.
About Quanterix
From discovery to diagnostics, Quanterix’s ultra-sensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806815882/en/
Media:
PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com
Investor Relations:
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com
Source: Quanterix Corporation
